Lyn-analyse Novo Nordisk kan være på vej med en reel gamechanger

Novo har længe haltet efter konkurrenten Eli Lilly på det vigtige amerikanske marked. Men en ny fedmepille kan være en reel gamechanger for selskabet i Bagsværd. Spørgsmålet er bare om investorerne ser det på samme måde og om Eli Lilly har en joker i ærmet.  Lyt til denne Lyn-analyse og hør, hvorfor det er så vigtigt for Novo at komme først med pillen og hvad jokeren fra konkurrenten er?  Gæst: Nick Sturm, journalist, Finans.  Vært: Mads Ring.  Foto: Gregers Tycho.See omnystudio.com/listener for privacy information.

Episode metadata supplied by the publisher feed · Published Oct 20, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Lyn-analyse Novo Nordisk kan være på vej med en reel gamechanger

0:00 7:50

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Finans Podcast?

This episode is 7 minutes long.

When was this Finans Podcast episode published?

This episode was published on October 20, 2025.

Can I download this Finans Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!